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ABSTRACT
Chlamydia trachomatis is the most common bacterial sexually-transmitted pathogen for which there is
no vaccine. We previously demonstrated that the degree of phosphate substitution in an aluminum
hydroxide adjuvant in a TLR-4-based C. trachomatis serovar E (Ser E) recombinant major outer mem-
brane protein (rMOMP) formulation had an impact on the induced antibody titers and IFN-γ levels. Here,
we have extended these observations using outbreed CD-1 mice immunized with C. trachomatis Ser
E rMOMP formulations to evaluate the impact on bacterial challenge. The results confirmed that the
rMOMP vaccine containing the adjuvant with the highest phosphate substitution induced the highest
neutralizing antibody titers while the formulation with the lowest phosphate substitution induced the
highest IFN-γ production. The most robust protection was observed in mice vaccinated with the
formulation containing the adjuvant with the lowest phosphate substitution, as shown by the number
of mice with positive vaginal cultures, number of positive cultures and number of C. trachomatis
inclusion forming units recovered. This is the first report showing that vaccination of an outbred strain
of mice with rMOMP induces protection against a vaginal challenge with C. trachomatis.
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Chlamydia trachomatis is the most common sexually-transmitted
bacterial infection worldwide.1,2 Genital infections affect mainly
sexually-active teenagers.3-5 Newborns can become infected in
the birth canal and contract ocular, respiratory and gastrointest-
inal infections.6-8 Trachoma, a chronic C. trachomatis ocular
infection, affecting regions with poor sanitary conditions, is the
most common cause of preventable blindness globally.9-11
The clinical sequelae, such as trachoma and pelvic inflamma-
tory disease, are thought not to be directly caused by the pathogen
itself, but by induced immune responses, which can clear the
infection but can also cause collateral damage.9,12,13
C. trachomatis attracts innate and antigen-specific cells that release
immune factors, such as chemokines and cytokines, which are
likely to be responsible for the pathology. Results from studies in
mice suggest that this pathogenesis is dependent on signaling
through toll-like receptor 2 (TLR2), but not TLR4, although both
TLR2- and TLR4-deficient mice can clear the infection as well as
wild-type mice.14 Studies in humans and mice have shown that
TLR2 is the primary pathogen-recognition receptor in the upper
genital tract that drives the immune-pathogenicmechanisms asso-
ciated with C. trachomatis infections.14,15
Many developed countries run C. trachomatis screening pro-
grams, although there are gaps in the evidence base for their
efficacy.16 The European Center for Disease Prevention and
Control (ECDC) recommends national strategies for
C. trachomatis control, which include screening programs for at-
risk individuals and an evaluation plan for the strategy.
Antibiotic therapy is effective against C. trachomatis infections,
but due to inappropriate treatment and the large number of
asymptomatic patients, long-term sequelae including abdominal
pain, infertility, ectopic pregnancy, lymphogranuloma venereum
and blindness, can occur.4,5,11,17 The prevalence rate of genital
infections has been reported to increase in countries that have
established screening programs.18,19 This increase is thought to
be due to reduced duration of infection, resulting from antibiotic
therapy, which prevents the development of natural immunity.18
Therefore, vaccination could be the best approach to prevent
C. trachomatis infections and reduce the burden of disease.20-25
The major outer membrane protein (MOMP), one of the most
abundant, immunogenic chlamydial proteins, has been shown to
elicit protective immunity in mice, similar to that induced by
natural infection.26
Both innate and adaptive immune responses are elicited by
natural C. trachomatis infections, with IFN-γ and IL-17 play-
ing important roles as key effectors for both protection and
pathological responses.27 At high concentrations, IFN-γ kills
the bacteria but at low concentrations, it can enhance patho-
logical responses.12,13 Hence, effective vaccines need to strike
CONTACT Luis M. de la Maza lmdelama@uci.edu Department of Pathology and Laboratory Medicine, Medical Sciences I, University of California, Room
D440, Irvine, CA 92697-4800, USA
HUMAN VACCINES & IMMUNOTHERAPEUTICS
https://doi.org/10.1080/21645515.2020.1717183
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
the correct balance between inducing a protective response
and triggering a pathological reaction.
Phosphate substitution in aluminum-based adjuvants has
been reported to modify the immunogenicity of various anti-
gens in vaccine formulations. For example, in an anthrax
vaccine containing recombinant protective antigen (rPA)
and an aluminum oxyhydroxide AlOOH adjuvant, it was
reported that high phosphate substitution was associated
with a higher immune response to rPA.28 The authors sug-
gested that this was due to a weaker interaction between rPA
and the phosphorylated adjuvant that allowed a more com-
plete water layer between the components and therefore
resulted in a rapid release of rPA after injection.
Phosphate substitution in AIOOH-containing adjuvant can
affect the adsorption and stability of vaccine components which
can have an impact on the bioavailability of antigens, TLR
agonists and thus the vaccine’s efficacy.29-31 This phosphate
substitution can be achieved by pretreating the AIOOH-
containing adjuvant with varying concentrations of phosphate
ions in the form of potassium or sodium phosphate.30,31 The
phosphate ions displace the surface hydroxyl thereby decreasing
its point of zero charge. We recently reported that the cellular
and humoral immune responses to a vaccine containing recom-
binant C. trachomatis serovar E MOMP, and a proprietary adju-
vant (SPA08), composed of AIOOH and the TLR4 agonist,
E6020, were dependent on the degree of phosphate substitution
on the AlOOH component.32
The use of inbred strains of mice has greatly facilitated initial
testing of experimental vaccine formulations by providing
invaluable data on the assessment of the immune responses of
the host which can help improve the protective efficacy of
vaccine formulations. Inbred animals only provide information
on a limited range of the possible immune responses observed in
humans following vaccination. The high incidence and preva-
lence of chlamydial infections in all parts of the world affecting
individuals with very different genetic backgrounds requires
vaccine formulations to be tested in outbred individuals.
The initial studies assessing protection against trachoma
were performed in various models, including humans and
non-human primates.11 Most of the work done recently to
assess the protective efficacy of vaccine formulations against
genital infections utilized inbred mice, in particular C3H/
HeN, BALB/c and C57BL/6 mice.33 Currently, one of the
most extensive vaccine studies in an outbred species of ani-
mals is being performed in koalas (Phascolarctos cinereius).34
These animals that are naturally infected in the eyes and the
genitourinary tract by Chlamydia pecorum, suffer long-term
sequelae including blindness and infertility, like humans and
therefore major efforts are underway to protect them with
a vaccine using MOMP as the antigen.35-38
In the context of preclinical development of a human
C. trachomatis vaccine, we focused on serovar E rMOMP as
a model antigen since serovar E is the most prevalent serovar
in human urogenital infections and also the one that induces the
highest serological responses.39-42 Here, we report how phos-
phate substitution affected the ability of the rMOMP vaccine to
protect outbreed CD-1 mice against a vaginal challenge with
C. trachomatis serovar E. This was achieved using vaccine for-
mulations with different degrees of phosphate substitution on
the AlOOH-containing adjuvant, mentioned above, and another
formulation containing aluminum phosphate, to represent
a high degree of adjuvant phosphate substitution.
Materials and methods
C. trachomatis stocks
Stocks ofC. trachomatis serovar E (strain Bour) were prepared in
Hela-229 cell culture (American Type Culture Collection,
Manassas, VA). Elementary bodies (EBs) were purified using
Renografin and frozen at −70°C in SPG (0.02 sucrose, 0.2 M
sodium phosphate, pH 7.2, and 5 mM glutamic acid).43 The titer
of the EB stocks was determined using HeLa-229 cells.43
Vaccine formulations
The recombinant C. trachomatis serovar E (strain Bour)
MOMP (Ser E rMOMP) was expressed in Escherichia coli as
inclusion bodies (IBs). Briefly, bacteria were grown in a 20-L
fermenter with constant agitation at 37°C, pH 7 and 30%
dissolved oxygen. The IBs were extracted and solubilized in
6M guanidine hydrochloride and then exchanged with 8M
urea using tangential flow filtration (TFF). The urea solution
was applied to an anionic exchange chromatography column
(Q Ceramic HyperD® 20 Chromatography Sorbent, Pall
Corporation) and Ser E rMOMP was eluted from the column
with 50–90 mM sodium chloride. The eluted Ser E rMOMP
was refolded by mixing with equal volumes of 10% v/v
N-lauroyl sarcosine (NLS), 1 M 1-arginine and dithiothreitol
(DTT) to a final concentration of 10 mM. This mixture then
underwent buffer exchange with 10 mM Tris-HCl pH 8,
0.06% NLS diafiltration buffer using TFF and a membrane
filter with a molecular weight cutoff of 10 kDa. The prepara-
tion underwent a second TFF with 50 mM Tris-HCl, pH 8.0
diafiltration buffer. The final purity of the Ser E rMOMP was
greater than 90%, as evaluated by SDS-PAGE.
Aluminum hydroxide adjuvant (AlOOH) and aluminum
phosphate adjuvant (AlPO4) were acquired from Brenntag
(Frederikssund, Denmark). The SPA08 adjuvant was com-
posed of the TLR4 agonist, E6020 (Eisai, USA), adsorbed
onto AlOOH. Three SPA08 adjuvanted formulations contain-
ing 10 µg of Ser E rMOMP and 40 μg/mL E6020, 2.4 mg/mL
elemental Al and no phosphate (SPA08-1), 88 mM (SPA08-3)
or 176 mM (SPA08-4) phosphate were prepared as described
previously.32 The phosphate to aluminum molar ratio (P:Al)
of each adjuvant formulation is reported in Table 1. The
SPA08-2 formulation, with 8.8 mM phosphate, was not
assessed in this study as its immunological characteristics
were previously shown to be similar to those of SPA08-1.
An aluminum phosphate-based formulation (APF) with
a high degree of phosphate substitution (APF/rMOMP) con-
taining 10 µg of Ser E rMOMP was used for comparison.
Physicochemical characterization of formulations
The zeta potential, particle size distribution and percentage of
MOMP adsorbed for the three SerE MOMP-SPA08 formula-
tions were determined as previously described.32
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Mice
Six-week-old outbred female CD-1 mice (Charles River
Laboratories) were housed at the University of California,
Irvine (UCI) in isolation cubicles at a constant temperature
of 24°C with a 12 h light/12 h darkness cycle and fed chow
and water ad libitum. The UCI Animal Care and Use
Committee approved the animal protocols.
Vaccination protocol
Vaccine formulations containing C. trachomatis Ser E MOMP
and SPA08 or APF were extemporaneously prepared in 3 ml
glass vials by mixing one volume of Ser E rMOMP stock
solution with one volume of the SPA08-1, SPA08-3, SPA08-
4 or APF adjuvants. The formulations were mixed manually
by inverting the container at least five times to ensure thor-
ough mixing before injecting the mice or conducting physi-
cochemical characterization.
Groups of mice were vaccinated intramuscularly (IM)
three times at 3-week intervals with 50 µL of the SPA08-1,
SPA08-3, SPA08-4 or APF formulations (Figure 1). For each
formulation, a group of mice was sham-vaccinated at the
same time with the same volume of inoculum containing non-
phosphate treated SPA08 or APF in phosphate buffered saline
(PBS) with no Ser E rMOMP.
ELISA for C. trachomatis Ser E rMOMP-specific
antibodies
Blood was collected for IgG measurements and sero-
neutralization assays by periorbital puncture the day before the
vaginal challenge. C. trachomatis Ser E MOMP specific IgG,
IgG1, IgG2a titers were measured by an enzyme-linked immu-
nosorbent assay (ELISA) as described previously.32,44 Briefly, 96-
well plates were coated with EBs in PBS at a concentration of
10 µg per ml (1 μg/well), and blocked with PBS-Tween-milk
(0.05% Tween, 1% (w/v) powdered skim milk). The following
steps were then carried out in a final volume of 100 µL, followed
by three washes with PBS-Tween. Serial 2-fold dilutions of
serum samples in PBS-Tween-milk starting from 1/1,000, or 1/
10,000, were incubated at 37°C for 1 h. After washing the wells,
horseradish peroxidase-conjugated goat anti-mouse IgG, IgG1
or IgG2a (BD Pharmingen, San Diego, CA) were added and the
plates incubated for 1 h at 37°C. After washing, 2,2ʹ-azinobis
(3-ethylbenthiazoline-6-sulfonic acid) (ABTS) was added to the
wells and the plates incubated at 37°C for 1 h. The optical density
at 405 nm in the wells was measured in an ELISA plate reader
(Bio-Rad Laboratories, Richmond, CA).
In vitro sero-neutralization assay
In vitro sero-neutralization assays, performed in 96-well plates
as described previously, were repeated three times on different
Table 1. Physicochemical characteristics of Ser E rMOMP-SPA08 formulations.
Adjuvant P:Al molar ratio Zeta potential (mV) Size (d50) (µm)
% Adsorption
E6020 Ser E
SPA08-1 0 20.0 ± 1.1 4.6 ± 0.0 100.0 ± 0.0 100.0 ± 0.0
SPA08-3 1 −19.7 ± 3.4 4.0 ± 0.3 100.0 ± 0.0 68.9 ± 16.6
SPA08-4 2 −29.9 ± 6.4 4.8 ± 0.0 100.0 ± 0.0 44.2 ± 13.3
APF NA −33.0 ± 2.4 2.6 ± 0.1 100.0 ± 0.0 41.9 ± 0.2
Figure 1. Schematic representation of study design.
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days.32 Briefly, two-fold serial dilutions of mouse sera in Ca2+-
and Mg2+-free PBS, pH 7.2, supplemented with 5% guinea pig
serum were incubated with C. trachomatis Ser E [1x104 infec-
tious forming units (IFU)] for 45 min at 37°C. The mixtures
were added to HeLa-229 cell monolayers, centrifuged for 1 h
and incubated at 37°C for 48 h. After washing, the monolayers
were fixed with methanol and stained with an in-house
monoclonal antibody E4 to MOMP.44 The titer of a sample
was the dilution that yielded 50% neutralization relative to the
negative control serum from sham-vaccinated mice.
Cell-mediated immune responses: IFN-γ determination
To assess T-cell memory responses, cytokine production was
measured in splenic T-cells from five mice per group eutha-
nized the day before the challenge.44,45 In brief, T-cell-
enriched splenocytes (105 cells/well) were co-cultured with
antigen presenting cells (APCs; 1.25 x 105/well), prepared by
irradiating syngeneic, unseparated splenocytes from the har-
vested spleens (3,000 rads; 137Cs), and then incubated for two
hours with either UV-inactivated C. trachomatis Ser E EB at
a 1:1 ratio or purified Ser E rMOMP. Concanavalin A was
included as a positive control. The supernatants were har-
vested and stored at −80°C until used for the determination of
the IFN-γ concentrations by ELISA (BD Pharmingen, San
Diego, CA; Labsystem Multiscan; Helsinki, Finland).
Vaginal challenge
Four weeks after the third vaccine dose the mice were challenged
vaginally.46-49 The mice were injected with 2 mg of DepoProvera
subcutaneously twice prior to the vaginal challenge (days −10
and −3) to synchronize their estrus cycle in diestrus. The mice
were anesthetized and C. trachomatis Ser E (Bour) (105 IFU)
were inoculated into their vaginas. The mice were kept in
a recumbent position for 10–15 min after the challenge.
Vaginal swabs were collected and cultured twice weekly for
the first three weeks, and then once-a-week in weeks 4, 5, and
6 after the vaginal challenge (Figure 1).47 The swabs were
vortexed in 200 μl of sterile SPG and two aliquots from each
specimen (100 μl and 10 μl) were inoculated into HeLa-229
cell monolayers in 48-well plates by centrifugation at 1,000xg
for 1 h at room temperature. Following incubation at 37°C for
48 h, the chlamydial inclusions were stained with an in-house
monoclonal antibody (E4) to MOMP.50
The following criteria were used to determine protection:
number of mice with positive vaginal cultures, number of
positive vaginal cultures over total number of cultures col-
lected, number of C. trachomatis IFU recovered and length of
time of vaginal shedding.
Hydrosalpinx formation
Seven weeks after the vaginal challenge mice were euthanized
and their genital tract macroscopically investigated to deter-
mine the presence of hydrosalpinx which is an indicator of
upper genital tract pathology.51
Statistical analyses
Using a computer model, it was shown that even a vaccine
with 50% efficacity would have a significant impact on the
clearance of Chlamydia from a defined community.20 Thus,
the sample size was based on a criterion of at least 50%
efficacity. The number of mice included in the experiments
was based on previously published recommendations.52
Student’s t test, Fisher’s exact test and Mann-Whitney
U test were used for analyses performed using SigmaStat
(version 3.5) software. Differences were considered statisti-
cally significant when the p-values was <0.05.
Results
Characterization of vaccine formulations
The SPA08 adjuvant was treated with phosphate ions to
increase the phosphate substitution on the AlOOH compo-
nent to investigate the impact of Ser E rMOMP adsorption
on the immunogenicity and protection of the vaccine. The
impact of type of aluminum salt and adsorption on immu-
nogenicity and protection was also evaluated using an alu-
minum phosphate version of the adjuvant (APF), with
identical amounts of Ser E rMOMP. The physicochemical
characterization of the SPA08 formulations indicated that
the zeta potential at neutral pH decreased as the P:Al molar
ratio increased, but there was no effect on the particle size or
E6020 adsorption (Table 1). The percentage of Ser
E rMOMP adsorption to AlOOH in the formulation at
neutral pH decreased as the phosphate substitution
increased primarily due to high electronegativity of the
SPA08 adjuvant at high P:Al ratios which decreased the
electrostatic interaction between Ser E rMOMP and SPA08
at neutral pH (Table 1). In contrast, E6020 remained bound
to AlOOH, irrespective of the amount of phosphate
substitution.
The physicochemical characteristics of the formulation
containing APF adjuvant were similar to those of SPA08-4,
with a strongly negative zeta potential and comparable Ser
E rMOMP percentage adsorption (Table 1). However, the
particles in the APF formulation were significantly smaller
than those in the SPA08-adjuvanted formulations.
Association of P:Al molar ratio with total C. trachomatis
Ser E rMOMP-specific IgG levels and their neutralizing
capacity
Ser E rMOMP-specific antibody response
High IgG titers in serum were observed in the four groups of
mice immunized with C. trachomatis Ser E rMOMP indepen-
dently of the adjuvant formulation used (Figure 2). Although
mice immunized with SPA08-1 had lower IgG geometric
mean titers (GMTs) (877,997; range 398,099–1,936,000) than
those immunized with SPA08-3 (1,882,000; range 1,375,000–-
2,575,000), SPA08-4 (1,529,000; range 1,153,000–2,027,000) or
APF (2,940,668; range 1,280,000–5,120,000) the differences
were not statistically significant.
The IgG2a GMTs increased as the P/Al molar ratios
increased (Figure 2). Similar IgG1 GMTs were elicited by
4 S. PAL ET AL.
SPA08-1 and SPA08-3, while the IgG1 GMTs elicited by
SPA08-4 and APF were higher. The IgG1/IgG2a ratio for
APF was 5.7 compared with a range from 0.93 to 2.3for the
SPA08 formulations.
In vitro sero-neutralization assay
Serum antibodies were evaluated for their ability to neutralize
C. trachomatis Ser E infectivity in vitro (Figure 3). There was
a trend for more mice to have neutralizing antibodies as the P:
Al molar ratio increased: 12/19 (63%) in the SPA08-1 group;
8/10 (80%) in the SPA08-3 group and 20/20 (100%) in the
SPA08-4 group. Positive neutralizing titers were observed in
7/10 (70%) of the mice in the APF group. The neutralizing
GMTs were 141 (range: 25–51,200), 397 (range: 25–51,200),
1,685 (range: 100–102,400), and 422 (range: 40–40,960) for
the SPA08-1, SPA08-3, SPA08-4, and APF groups,
respectively.
Association of P:AL molar ratio with ser E rMOMP-specific
IFN-γ production
Ser E MOMP-specific cellular responses were tested by ex vivo
stimulation of primed spleen T-cell with either Ser E EBs (Ct-
E EB) or purified Ser E rMOMP. T-cell stimulation with
purified Ser E rMOMP led to more IFN-γ production than
stimulation with EBs for all three SPA08 groups (Table 2).
The IFN-γ levels were higher for the SPA08-1 and SPA08-3
groups than those in the SPA08-4 group for both type of
stimuli. The primed spleen cells from APF-immunized mice
secreted the lowest quantities of IFN-γ when stimulated with
either Ser E EB or rMOMP (Table 2).
Culture results following vaginal challenge
Vaginal swabs were collected from the CD-1 mice following
the vaginal challenge twice weekly for the first three weeks
and weekly thereafter. There were fewer mice with at least one
positive vaginal culture in the rMOMP/SPA08-1 and
rMOMP/SPA08-3 groups compared with their respective
sham-vaccinated control groups, but not in the rMOMP/
SPA08-4 group, however, the differences were not statistically
significant (Figure 4; Table 3). The median number of days to
Figure 2. C trachomatis rMOMP serovar E-specific antibody titers determined by ELISA. Serum samples were drawn four weeks after the third vaccine dose from 10
mice. Each dot represents the results for one mouse and the horizontal lines represent the geometric mean titer (GMT) for the group of mice.
Figure 3. In vitro neutralization titers in sera drawn four weeks after the third
vaccine dose. Each dot represents one mouse and the horizontal line indicates
geometric mean titers (GMT).
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negative culture was significantly shorter in the vaccinated
groups compared with the sham-vaccinated control groups,
except for the rMOMP/APF group. Infection was cleared
faster in the rMOMP/SPA08-1 and rMOMP/SPA08-3 groups
than in the rMOMP/SPA08-4 and rMOMP/APF groups.
Moreover, there was no difference in the range of number
of days to negative culture between rMOMP/APF and its
sham-vaccinated control group. Significant differences in the
median number of IFUs recovered/mouse were observed for
the SPA08-1 and SPA08-4 groups and their respective sham-
vaccinated control groups, but not for the SPA08-3 and APF
and their sham-vaccinated control group. The mice in the
APF immunized group were not protected compared with
the mice in the sham-immunized group.
Upper genital tract pathology: hydrosalpinx formation
To determine protection against long-term sequelae, at seven
weeks following the vaginal challenge mice were euthanized
and their genital tract macroscopically inspected. None of the
mice had findings consistent with hydrosalpinx formation,
suggesting limited upper genital tract pathology.
Discussion
We have previously shown that phosphate substitution in the
adjuvant used in a C. trachomatis Ser E rMOMP/SPA08
vaccine increased MOMP-specific IgG and decreased IFN-γ
secretion in immunized mice.32 In the current study, we
confirmed that as the P:Al molar ratio in the Ser
E rMOMP/SPA08 vaccine formulations increased, the ELISA
and neutralizing antibody titers also increased while the IFN-
γ cellular response decreased. Hence, the formulation with the
highest P:Al ratio, SPA08-4, compared with the other formu-
lations, induced the highest neutralizing antibody GMT and
the lowest IFN-γ cellular response. This formulation was
associated with the lowest protection in the C. trachomatis
vaginal challenge mouse model, thus, it would seem that high
IFN-γ (Th1 response), rather than neutralizing antibodies,
correlated better with protection in this model. The compo-
nent within the vaccine that polarizes the rMOMP immunity
toward an IFN-γ immune response profile and critically con-
tributes to protection is the TLR4 agonist, E6020. This serves
as a cautionary tale the fact that small changes within the
formulation, unrelated to the concentration of antigen or
TLR4 agonist, can turn a protective vaccine with a type
I immune profile into a non-protective vaccine with
a predominantly type II character, with far-reaching implica-
tions. The mechanisms by which phosphate substitution, pro-
tein adsorption and TLR-agonist adsorption influence the
profile of the immune response against rMOMP are currently
unknown. It is, however, plausible that these critical formula-
tion parameters impact the residence time of the antigen and
TLR-agonist at the site of injection, the uptake of the adju-
vant – antigen complex by APCs and antigen
presentation.32,53
The role of IFN-γ in clearance and protection against
chlamydia infection is supported by evidence from both
human and animal studies.54-57 Despite the vigorous antibody
response to chlamydia infection or in vaccine models across
different mammalian species, the role of antibodies is still
poorly understood with some studies reporting protection
and others a disease-enhancing effect.58-60 This is not surpris-
ing due to the huge heterogeneity of the antibody responses
and our incomplete understanding of this critical component
of the immune system. The results from in vitro experiments
performed decades ago demonstrated that following
a C. trachomatis infection, mice mounted humoral responses
that resulted in the production of antibodies some of which
were protective and others which had neutral or disease
enhancing effects.50,59,61 The protective effect of monoclonal
and polyclonal antibodies against MOMP has also been
shown in passive transfer experiments.58,62-64 The only
C. trachomatis vaccine undergoing evaluation in clinical trials
is based on a polyvalent recombinant MOMP formulation
that elicits high levels of neutralizing antibodies.58,65,66
The Ser E rMOMP/APF formulation induced a neutralizing
antibody response characterized by high levels of total IgG,
predominantly IgG1 subclass, and low levels of IFN-γ, suggestive
of a type II immune response, primarily. However, it did not
provide protection. This demonstrates that, in the present
model, Ser E rMOMP antibodies with in vitro neutralizing
capacity failed to protect against C. trachomatis Ser
E challenge, therefore, the protection would appear to be depen-
dent on an IFN-γ-mediated mechanism. The apparent discor-
dance between the in vivo and in vitro results could be explained
by the fact that the rMOMP antibodies exert their function via Fc
receptors (FcRs) in vivo but that the FcRs are not necessary for
in vitro neutralization. Also, the antibody isotype and the host
cell type used for the in vitro neutralization assay can affect the
results.50,59,61 Thus, this apparent negative effect is likely to be
due to this particular vaccine preparation since protective results
have been observed with rMOMP and native MOMP in other
Table 2. IFN-γ levels from stimulated spleen T-cells taken four weeks after the third vaccination from five mice in each group.
Groups
IFN-γ levels (pg/ml, mean ± 1 SE) in response to:
Ct-E EB Ct-E-rMOMP Concanavalin A Medium
SPA08-1 Vaccinated 7,538 ± 817a 15,563 ± 2,122a 36,351 ± 5,933 <15
Control <15 <15 19,311 ± 2,492 <15
SPA08-3 Vaccinated 2,748 ± 450a 11,206 ± 404a 45,599 ± 4,429 <15
Control <15 <15 43,226 ± 3,335 <15
SPA08-4 Vaccinated 1,814 ± 1,837a 5,416 ± 1,815a 15,848 ± 1,669 <15
Control <15 <15 26,045 ± 2,965 <15
APF Vaccinated 1,679 ± 265a 1,166 ± 455a 37,593 ± 1,558 <15
Control <15 <15 48,682 ± 1,284 <15
aP<0.05 by the Student’s t test compared to corresponding PBS control group.
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formulations.21,26,65,67-69 As seen with other recombinant vac-
cines, such as those for HBV and HPV, many of the highly
protective B-cell epitopes are located in conformation-
dependent domains. Thus, it may be that in this model the
humoral immune protective responses are not fully achieved
and hence play a secondary role to the cell-mediated immune
responses.70-73 Future studies such as passive immunity transfer
with different subclasses of rMOMP antibodies, could address
Figure 4. Vaginal culture results in samples taken at 4, 6, 8, 11, 13, 15, 18, 21, 28, 35 and 42 days after vaginal challenge with C. trachomatis Ser E.
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this question to improve our understanding about which anti-
body-dependent mechanisms are protective and to de-risk
further attempts to develop chlamydia vaccines.
The search for an effective C. trachomatis vaccine started
more than a century ago, and although whole-organism vac-
cines were found to induce protective responses, their devel-
opment stopped when enhanced disease was observed in
some immunized individuals, a phenomenon known as vac-
cine-related immunopathology.9,11,21,23,74,75 Although this
phenomenon is rare, it has been reported for other infectious
diseases, such as RSV and measles.76,77 The rMOMP antigen,
produced by recombinant technology in E. coli, is free from
chlamydial contaminants that could be responsible for
unwanted immune responses.
The efficacy of experimental vaccine formulations is tested
in different animal models.78,79 To facilitate the interpretation
of immunological responses the majority of vaccination
experiments in animal models are performed in inbreed
strains. This approach is extremely helpful for characterizing
immune responses to vaccination and determining which
correlate with protection. A limitation of using inbred animals
is that they do not have the highly heterogeneous genetic
diversity that humans have. The heterogeneous human
genetic diversity means their response to the same immuno-
logical stimuli can vary. To mimic the heterogeneity better, we
used outbred female CD-1 mice in this study. To our knowl-
edge this is the first report of vaccine-induced protection in
an outbred mouse strain against a vaginal challenge with
C. trachomatis. This represents a significant step forward in
chlamydia vaccine development. Previous reports have shown
protection using homologous rMOMP in inbred mice chal-
lenged in the genital tract with C. trachomatis or
C. muridarum.65,67,80
One limitation of the study is the lack of overt pathogeni-
city of the C. trachomatis serovar E in mice. The serovar E is
a human pathogen with little affinity for murine cells and
tissues which could explain its lack of pathogenicity.
Moreover, C. trachomatis is generally not very virulent, even
in humans. Infections are frequently asymptomatic, with overt
pathogenicity in female upper genital tract typically detected
only during severe acute infections or after years of chronic
infection. Hence, reproducing C. trachomatis pathology in
a time-contracted animal model is a challenge. The absence
of hydrosalpinx formation, an indicator of upper genital tract
pathology, confirms that none of the vaccinated or sham-
vaccinated control mice developed long-term sequelae during
the study. These results support the limited pathogenic nature
of C. trachomatis in mice when delivered by the vaginal
route.81-83
In conclusion, our results showed that the SPA08 vaccine
formulation with no phosphate substitution provides better
protection than formulations with phosphate substitution
against a vaginal C. trachomatis challenge in mice, probably
via a Th1 mechanism. Furthermore, it establishes the ability of
a vaccine formulated with rMOMP to elicit protection in
individuals with a broad diversity of genetic backgrounds.
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